<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA Psychiatry: Cardiology Topic Collection</title>
    <link>http://archpsyc.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Wed, 06 Feb 2013 00:00:00 GMT</pubDate>
    <lastBuildDate>Wed, 06 Feb 2013 15:44:37 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@archpsyc.jamanetwork.com</managingEditor>
    <webMaster>webmaster@archpsyc.jamanetwork.com</webMaster>
    <item>
      <title>Meta-analysis of Functional Magnetic Resonance Imaging Studies of Inhibition and Attention in Attention-deficit/Hyperactivity Disorder Exploring Task-Specific, Stimulant Medication, and Age Effects  ADHD Functional MR Imaging Studies Meta-analysis </title>
      <link>http://archpsyc.jamanetwork.com/article.aspx?articleID=1485446</link>
      <pubDate>Fri, 01 Feb 2013 00:00:00 GMT</pubDate>
      <author>Hart H, Radua J, Nakao T, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Context&lt;/div&gt;Functional magnetic resonance imaging studies in attention-deficit/hyperactivity disorder (ADHD) revealed fronto-striato-parietal dysfunctions during tasks of inhibition and attention. However, it is unclear whether task-dissociated dysfunctions exist and to what extent they may be influenced by age and by long-term stimulant medication use.&lt;div class="boxTitle"&gt;Objective&lt;/div&gt;To conduct a meta-analysis of functional magnetic resonance imaging studies in ADHD during inhibition and attention tasks, exploring age and long-term stimulant medication use effects.&lt;div class="boxTitle"&gt;Data Sources&lt;/div&gt;PubMed, ScienceDirect, Web of Knowledge, Google Scholar, and Scopus databases were searched up to May 2012 for meta-analyses. Meta-regression methods explored age and long-term stimulant medication use effects.&lt;div class="boxTitle"&gt;Study Selection&lt;/div&gt;Twenty-one data sets were included for inhibition (287 patients with ADHD and 320 control subjects), and 13 data sets were included for attention (171 patients with ADHD and 178 control subjects).&lt;div class="boxTitle"&gt;Data Extraction&lt;/div&gt;Peak coordinates of clusters of significant group differences, as well as demographic, clinical, and methodological variables, were extracted for each study or were obtained from the authors.&lt;div class="boxTitle"&gt;Data Synthesis&lt;/div&gt;Patients with ADHD relative to controls showed reduced activation for inhibition in the right inferior frontal cortex, supplementary motor area, and anterior cingulate cortex, as well as striato-thalamic areas, and showed reduced activation for attention in the right dorsolateral prefrontal cortex, posterior basal ganglia, and thalamic and parietal regions. Furthermore, the meta-regression analysis for the attention domain showed that long-term stimulant medication use was associated with more similar right caudate activation relative to controls. Age effects could be analyzed only for the inhibition meta-analysis, showing that the supplementary motor area and basal ganglia were underactivated solely in children with ADHD relative to controls, while the inferior frontal cortex and thalamus were underactivated solely in adults with ADHD relative to controls.&lt;div class="boxTitle"&gt;Conclusions&lt;/div&gt;Patients with ADHD have consistent functional abnormalities in 2 distinct domain-dissociated right hemispheric fronto-basal ganglia networks, including the inferior frontal cortex, supplementary motor area, and anterior cingulate cortex for inhibition and dorsolateral prefrontal cortex, parietal, and cerebellar areas for attention. Furthermore, preliminary evidence suggests that long-term stimulant medication use may be associated with more normal activation in right caudate during the attention domain.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">70</prism:volume>
      <prism:number xmlns:prism="prism">2</prism:number>
      <prism:startingPage xmlns:prism="prism">185</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">198</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/jamapsychiatry.2013.277</prism:doi>
      <guid>http://archpsyc.jamanetwork.com/article.aspx?articleID=1485446</guid>
    </item>
    <item>
      <title>Elevated C-Reactive Protein Levels, Psychological Distress, and Depression in 73 131 Individuals Elevated CRP Levels and Psychiatric Illness </title>
      <link>http://archpsyc.jamanetwork.com/article.aspx?articleID=1485898</link>
      <pubDate>Fri, 01 Feb 2013 00:00:00 GMT</pubDate>
      <author>Wium-Andersen M, Ørsted D, Nielsen S, et al. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Context&lt;/div&gt;The pathogenesis of depression is not fully understood, but studies suggest that low-grade systemic inflammation contributes to the development of depression.&lt;div class="boxTitle"&gt;Objective&lt;/div&gt;To test whether elevated plasma levels of C-reactive protein (CRP) are associated with psychological distress and depression.&lt;div class="boxTitle"&gt;Design&lt;/div&gt;We performed cross-sectional and prospective analyses of CRP levels in 4 clinically relevant categories using data from 2 general population studies.&lt;div class="boxTitle"&gt;Setting&lt;/div&gt;The Copenhagen General Population and the Copenhagen City Heart studies.&lt;div class="boxTitle"&gt;Participants&lt;/div&gt;We examined 73 131 men and women aged 20 to 100 years.&lt;div class="boxTitle"&gt;Main Outcome Measures&lt;/div&gt;We ascertained psychological distress with 2 single-item self-reports and depression using self-reported antidepressant use, register-based prescription of antidepressants, and register-based hospitalization with depression.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;In cross-sectional analyses, increasing CRP levels were associated with increasing risk for psychological distress and depression (P = 3 × 10&lt;sup&gt;−8&lt;/sup&gt; to P = 4 × 10&lt;sup&gt;−105&lt;/sup&gt; for trend). For self-reported use of antidepressants, the odds ratio was 1.38 (95% CI, 1.23-1.55) for CRP levels of 1.01 to 3.00 mg/L, 2.02 (1.77-2.30) for 3.01 to 10.00 mg/L, and 2.70 (2.25-3.25) for greater than 10.00 mg/L compared with 0.01 to 1.00 mg/L. For prescription of antidepressants, the corresponding odds ratios were 1.08 (95% CI, 0.99-1.17), 1.47 (1.33-1.62), and 1.77 (1.52-2.05), respectively; for hospitalization with depression, 1.30 (1.01-1.67), 1.84 (1.39-2.43), and 2.27 (1.54-3.32), respectively. In prospective analyses, increasing CRP levels were also associated with increasing risk for hospitalization with depression (P = 4 × 10&lt;sup&gt;−8&lt;/sup&gt; for trend).&lt;div class="boxTitle"&gt;Conclusions&lt;/div&gt;Elevated levels of CRP are associated with increased risk for psychological distress and depression in the general population.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">70</prism:volume>
      <prism:number xmlns:prism="prism">2</prism:number>
      <prism:startingPage xmlns:prism="prism">176</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">184</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/2013.jamapsychiatry.102</prism:doi>
      <guid>http://archpsyc.jamanetwork.com/article.aspx?articleID=1485898</guid>
    </item>
  </channel>
</rss>